knowledge -WSS

knowledge

author：explore 2025-09-30 17:59:42 - browse：34

Several amyloid plaques forming between neurons in a brain — Adobe

Expert advisers to the Food and Drug Administration on Friday voted unanimously in favor of expanding the approval of Leqembi, an Alzheimer’s disease treatment from Eisai and Biogen, further clearing the way for what could be the first widely available medicine that delays the disease’s progress.

The group voted 6-0 that an 1,800-patient study of Leqembi confirmed its benefits for patients in the early stages of Alzheimer’s, recommending the FDA widen the drug’s limited approval. The agency, which is not required to follow the suggestions of its advisers, is expected to make a final decision on Leqembi by July 6.

“I thought the clinical results were robust,” said Merit Cudkowicz, a neurologist from Massachusetts General Hospital and one of the experts invited to review Leqembi.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Alkermes shareholders re
Next article： Kale crackers and hibiscus tea: My five days on a 'fasting diet'

WSS

How to address the problem of discarded donor organs

Congress gives doctors Medicare pay bump

'Weather

Flu vaccine offering decent levels of protection this winter, new data show

Campaign finance charge dropped from case against Sam Bankman

A Q&A with Aletha Maybank, AMA’s chief health equity officer

hotspot

knowledge

knowledge

FDA approval of Sarepta Duchenne genetic therapy gives me hope

RaDonda Vaught to speak at CommonSpirit event on patient safety

The cancer drug shortage isn’t new — and neither are the solutions

Judge orders hearing on Trump's motion to disqualify Fulton County DA

Sports medicine is finally prioritizing gender equality

Judge orders hearing on Trump's motion to disqualify Fulton County DA

DIEP, the 'gold standard' of breast reconstruction, is under threat

Pfizer highlights cancer drugs it thinks could reignite investor interest

Trump demands the U.S. pay no more for drugs than other countries … again

Flu vaccine offering decent levels of protection this winter, new data show

focus

How to fix the rural physician shortage in the U.S.

International team creates first chimeric human

Medical device lobby: We're tired of waiting on Medicare coverage

China demands US invite Hong Kong leader to economic meeting, adding to strains over crackdown

ALS groups 'won't be played again' by the FDA, drug sponsors

Covid isolation guidance eased by the CDC

hotspot

knowledge

knowledge

entertainment